Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
U.S.-listed shares of Chinese firms such as Alibaba (NYSE: BABA) rose 2.8%, PDD Holdings climbed 4.4% and NetEase (NASDAQ: ...
POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, is pleased to announce the publication of positive findings in a peer-reviewed paper in the Journal of Medical Virology ...
A groundbreaking new drug to treat schizophrenia called Cobenfy, owned by pharmaceutical firm Bristol Myers Squibb, has been ...
Hurricane Helene left an enormous path of destruction across the entire southeastern U.S. on Friday, snapping trees like ...
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure, the personal consumption expenditures ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
U.S. stock indexes are drifting around their records Friday as hopes hold that the economy can pull off the rare feat of ...